An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1434-9949
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status ; volume:27 ; number:8 ; day:19 ; month:3 ; year:2008 ; pages:1021-1028 ; date:8.2008
Clinical rheumatology ; 27, Heft 8 (19.3.2008), 1021-1028, 8.2008
- Urheber
-
Bijl, Arie E. van der
Breedveld, Ferdinand C.
Antoni, Christian E.
Kalden, Joachim R.
Kary, Sonja
Burmester, Gerd R.
Beckmann, Christina
Unnebrink, Kristina
Kupper, Hartmut
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10067-008-0866-4
- URN
-
urn:nbn:de:101:1-2019100701190975708068
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bijl, Arie E. van der
- Breedveld, Ferdinand C.
- Antoni, Christian E.
- Kalden, Joachim R.
- Kary, Sonja
- Burmester, Gerd R.
- Beckmann, Christina
- Unnebrink, Kristina
- Kupper, Hartmut
- SpringerLink (Online service)
Ähnliche Objekte (12)
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Infliximab und Adalimumab in der Therapie der Colitis ulcerosa : eine retrospektive Analyse
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
PF-06438179/GP1111: An Infliximab Biosimilar
Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Infliximab und Adalimumab in der Therapie der Colitis ulcerosa : eine retrospektive Analyse
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
PF-06438179/GP1111: An Infliximab Biosimilar
Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Infliximab und Adalimumab in der Therapie der Colitis ulcerosa : eine retrospektive Analyse
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
PF-06438179/GP1111: An Infliximab Biosimilar